Use of web-based decision support to improve informed choice for chemoprevention: A qualitative analysis of pre-implementation interviews (SWOG S1904)

Authors

Alissa M. Michel, Columbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA. Am5314@cumc.columbia.edu.
Haeseung Yi, Columbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Jacquelyn Amenta, Columbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Nicole Collins, Columbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Anna Vaynrub, Columbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Subiksha Umakanth, Columbia University Irving Medical Center, 177 Fort Washington Ave, Suite 6-435, New York, NY, 10032, USA.
Thomas J. Saphner, Advocate Health - MidwestFollow
et al

Recommended Citation

Michel AM, Yi H, Amenta J, et al. Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904). BMC Med Inform Decis Mak. 2024;24(1):272. Published 2024 Sep 27. doi:10.1186/s12911-024-02691-0

Affiliations

Aurora NCORP, Milwaukee

Abstract

Background:Women with high-risk breast lesions, such as atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS), have a 4- to tenfold increased risk of breast cancer compared to women with non-proliferative breast disease. Despite high-quality data supporting chemoprevention, uptake remains low. Interventions are needed to break down barriers.

Methods:The parent trial, MiCHOICE, is a cluster randomized controlled trial evaluating the effectiveness and implementation of patient and provider decision support tools to improve informed choice about chemoprevention among women with AH or LCIS. For this pre-implementation analysis, 25 providers participated in semi-structured interviews prior to accessing decision support tools. Interviews sought to understand attitudes/beliefs and barriers/facilitators to chemoprevention.

Results:Interviews with 25 providers (18 physicians and 7 advanced practice providers) were included. Providers were predominantly female (84%), white (72%), and non-Hispanic (88%). Nearly all providers (96%) had prescribed chemoprevention for eligible patients. Three themes emerged in qualitative analysis. The first theme describes providers' confidence in chemoprevention and the utility of decision support tools. The second theme elucidates barriers to chemoprevention, including time constraints, risk communication and perceptions of patients' fear of side effects and anxiety. The third theme is the need for early implementation of decision support tools.

Conclusions:This qualitative study suggests that providers were interested in the early inclusion of decision aids (DA) in their chemoprevention discussion workflow. The DAs may help overcome certain barriers which were elucidated in these interviews, including patient level concerns about side effects, clinic time constraints and difficulty communicating risk. A multi-faceted intervention with a DA as one active component may be needed.

Trial registration:This trial was registered with the NIH clinical trial registry, clinicaltrials.gov, NCT04496739 .

Document Type

Article

PubMed ID

39334347